Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18006 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Tsz Hong Yiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Antibodies, Monoclonal, Pyrimidines. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real‐world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment.
Aim
To provide real‐world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD.
Methods
We conducted a systematic review of observational studies up to March 2023 assessing advanced therapies' persistence in UC and CD. Advanced therapies under examination included infliximab, adalimumab, vedolizumab, ustekinumab, golimumab, certolizumab and tofacitinib. We pooled the persistence of each agent and conducted a meta‐analysis to compare the persistence of newer agents with traditional TNF inhibitors (TNFi)—specifically infliximab and adalimumab.
Results
Among 63 observational studies, vedolizumab had the highest 1‐year persistence in UC (73.8%, 95% CI: 70.0%–77.6%) and ustekinumab in CD (77.5%, 95% CI: 72.9%–82.1%). Compared to TNFi, vedolizumab demonstrated increased persistence with a relative risk (RR) of 1.30 (95% CI: 1.19–1.41) for UC and 1.14 (95% CI: 1.09–1.20) for CD at 1 year, while ustekinumab demonstrated a RR of 1.15 (95% CI: 1.07–1.23) for CD at 1 year. Vedolizumab exhibited sustained increased persistence in UC over 2 years compared to TNFi (RR: 1.33, 95% CI 1.14–1.54).
Conclusion
This meta‐analysis highlights the superior persistence of ustekinumab and vedolizumab over TNFi, and offers valuable insights for clinicians navigating the challenging landscape of UC and CD therapeutic choices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
- Campbelltown and Camden Hospitals, Canterbury Hospital, Western Sydney University, Sydney, New South Wales, Australia.
- Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
- Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy.
- Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Zitieren
APA
Yiu, T. H., Ko, Y., Pudipeddi, A., Natale, P., & Leong, R. W. (2024). Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18006
Vancouver
Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18006
BibTeX
@article{Yiu2024,
author = {Yiu, Tsz Hong and Ko, Yanna and Pudipeddi, Aviv and Natale, Patrizia and Leong, Rupert W},
title = {Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18006}
}
EUVIMED